CorMedix Inc. to Present at 2016 Marcum MicroCap Conference

Written by Welcome on May 26, 2016

Bedminster, NJ – May 26, 2016 – CorMedix Inc. (NYSE…

CorMedix Inc. Presented Post-Market Clinical Utility Data from Neutrolin(R) Usage Monitoring Program at 53rd Joint Congress of the European Renal Association – European Dialysis and Transplant Association

Written by Welcome on May 23, 2016

Bedminster, NJ – May 23, 2016 – CorMedix Inc. (NYSE…

CorMedix Inc. Announces Publication of New Pharmacoeconomic Data Demonstrating Cost of Catheter-Related Infections at the ISPOR 21st Annual International Meeting

Written by Welcome on May 18, 2016

21st Annual International Society for Pharmacoeconomics and Outcomes Research Meeting…

CorMedix Inc. Reports First Quarter 2016 Financial Results

Written by Welcome on May 11, 2016

Conference Call Today at 9:00 a.m. Eastern Time Corporate Highlights:…

CorMedix Inc. Announces Agreement with NanoProteagen for its Proprietary Nanoparticle Technology, NanoPro™, in combination with CRMD-005 for Pediatric Neuroblastoma

Written by Welcome on May 11, 2016

Bedminster, NJ – May 11, 2016 – CorMedix Inc. (NYSE…

CorMedix Inc. Reports First Quarter 2016 Financial Results

Written by Welcome on May 11, 2016

CorMedix Inc. to Report First Quarter 2016 Financial Results

Written by Welcome on May 6, 2016

Conference Call to be held Wednesday, May 11, 2016, at…

CorMedix Announces Publication of Neutrolin® Data to be Presented at the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases

Written by Welcome on May 5, 2016

Bedminster, NJ – May 5, 2016 – CorMedix Inc. (NYSE…

CorMedix Appoints Myron Kaplan to Board of Directors

Written by Welcome on May 2, 2016

Bedminster, NJ – May 2, 2016 – CorMedix Inc. (NYSE…